1月13日 - ** 制药商TG Therapeutics TGTX.O股价在延时交易中上涨7%，报29.88美元
** 初步预计2025年全年净销售额为6.16亿美元，此前预计为6亿美元
** 预计2026年净销售额在8.75亿至9亿美元之间，而之前预计为8.956亿美元--数据由LSEG汇编
** 公司首席执行官魏斯（Michael Weiss）表示，如果多发性硬化症药物Briumvi获得批准，公司预计其新的静脉输注计划将在短期内提高收入。
** 2025 年股价小幅下跌
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.